Table 1 Additional clinical characteristics and demographic profiles of patients
From: Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience
Patient Characteristics | Value (N = 867) |
|---|---|
Patient age | |
median (range), y | 75 (51–96) |
Sex, No. (%) | |
Male | 565 (65) |
Female | 302 (35) |
Race, No. (%) | |
Caucasian | 801 (92) |
African American | 18 (2) |
Hispanic | 25 (3) |
Other | 19 (2) |
AML classification, No. (%) | |
De novo AML | 383 (44) |
Secondary AML | 483 (56) |
AML risk stratification, No. (%) | |
Favorable-risk group | 21 (2) |
Intermediate-risk group | 485 (56) |
Poor-risk group | 266 (31) |
History of prior or concurrent cancer, No. (%) | |
Hematologic malignancies | 34 (4) |
Solid tumors | 207 (24) |
Prior thrombosis (arterial/venous) | 126 (14) |
Growth factors, No. (%) | |
Before AML diagnosis | 167 (19) |
EPO | 101 (12) |
G-CSF | 58 (7) |
GM-CSF | 8 (1) |
Post AML diagnosis | 728 (84) |
Complete blood counts at diagnosis, No. (range) | |
WBC (× 109/L) | 3.165 (0.08–413.74) |
Hemoglobin (g/dL) | 9.3 (5.6–15.2) |
Platelet (× 109/L) | 46 (1–800) |
Treatment regimen, No. (%) | |
Chemotherapy | 250 (29) |
Hypomethylating agent | 240 (28) |
Best supportive care | 225 (26) |
BMI, No. (%) | |
≤ 35 kg/m2 | 820 (65) |
> 35 kg/m2 | 47 (5) |